Information de reference pour ce titreAccession Number: | 01451458-199807000-00006.
|
Author: | Lode, H.; Borner, K.; Koeppe, P.
|
Institution: | From the Department of Chest and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn, and Benjamin Franklin Klinikum, Freie Universitat Berlin, Berlin, Germany
|
Title: | |
Source: | Clinical Infectious Diseases. 27(1):33-39, July 1998.
|
Abstract: | : Fluoroquinolone antimicrobial agents are highly active against aerobic or facultative gram-negative bacilli. The fluoroquinolones have been shown to be very concentration dependent in their rates of killing and also have a postantibiotic effect against most gram-negative pathogens. These properties resemble those of aminoglycosides more than those of the [beta]-lactam antibiotics. In animal studies, once daily administration of a dose that produced a high peak concentration/minimal inhibitory concentration (MIC) ratio of >10-20:1 resulted in significantly better survival than did regimens in which the same daily dose was used on a more fractionated schedule. Studies in patients, most often with ciprofloxacin, demonstrated that the area under the concentration-time curve (AUC)/MIC ratio (AUIC) is the most important predictor of both clinical and microbiological cure. These findings, when combined with microbiological and pharmacokinetic data, provide the rationale and tools needed for targeting the dosage of fluoroquinolones to individual patients on the basis of pharmacokinetics and the susceptibilities of the bacterial pathogens.
(C) Copyright Oxford University Press 1998.
|
References: | 1. Craig WA. The inter-relationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
2. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(suppl A):37-46.
3. Gudmundsson S, Vogelman BS, Craig WA. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986;18(suppl E):67-73.
4. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98.
5. Vogelman BS, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
6. Vogelman BS, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
7. Lode H, Kemmerich B. Rational use of new antibiotics in respiratory infections. In: Pennington JE, ed. Respiratory infections-diagnosis and management. 3d ed. New York: Raven Press, 1994:767-77.
8. Dalhoff A, Ullmann U. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990;9:479-87.
9. Zeiler HJ, Voigt WH. Efficacy of ciprofloxacin in stationary phase bacteria in vivo. Am J Med 1987;82(suppl 4A):87-90.
10. Dalhoff A. Interaction of aminoglycosides and ciprofloxacin with bacterial membranes. In: Adam D, Hahn H, Opferkuch W, eds. The influence of antibiotics on the host-parasite relationship. Vol 2. Berlin: Springer, 1985:16-27.
11. Suerbaum S, Leying H, Kroll WP, Gmeiner J, Opferkuch W. Influence of [beta]-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli. Antimicrob Agents Chemother 1987;31:1106-10.
12. Chapman JS, Georgopapadakou NH. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother 1988;32:438-42.
13. Fernandes PB, Shipkowitz N, Swanson R. Comparative efficacy of the fluoroquinolones in experimental animal infections: correlation with in vitro potency and pharmacokinetics. In: Fernandes PB, ed. International telesymposium on quinolones. Barcelona: J. R. Prous, 1989:255-68.
14. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. Am J Med 1987;82(suppl 4A):12-20.
15. Crumplin GC, Kenwright, Hirst T. Investigations into the mechanisms of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 1984;13(suppl B):9-23.
16. Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991;10:267-74.
17. Dalhoff A. A review of quinolone tissue pharmacokinetics. In: Fernandes PB, ed. International telesymposium on quinolones. Barcelona: J.R. Prous, 1989:277-312.
18. Decre D, Bergogne-Berezin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993;31: 331-42.
19. Borner K, Hoffken G, Lode H, et al. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 1986;5:179-86.
20. Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis 1991;164:499-506.
21. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;91(suppl 6A):45-56.
22. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987;31: 1054-60.
23. Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993;31:789-98.
24. Drusano GL, Johnson D, Rosen M, Standiford MC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
25. Peloquin CA, Cumbo TJ, Nix DE, Sands M, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch Intern Med 1989;149:2269-73.
26. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategie for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37:1065-72.
27. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
28. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MIC's are similar. Antimicrob Agents Chemother 1994;38:2730-7.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 1058-4838
|
DOI Number: | https://dx.doi.org/10.1086/51462...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|